New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
17:34 EDTBSX, VASCVascular Solutions announces settlement of patent lawsuit with Boston Scientific
Vascular Solutions (VASC) announced that it has reached a settlement of its patent lawsuit with Boston Scientific Corporation (BSX) relating to patents in the area of coronary guide extension catheters. Vascular Solutions filed the original lawsuit in U.S. District Court for the District of Minnesota in May 2013, alleging that Boston Scientific infringed three patents owned by Vascular Solutions related to rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter. Boston Scientific filed a counterclaim in July 2013, alleging that Vascular Solutions infringed a patent owned by Boston Scientific related to rapid exchange guide extension technology by manufacturing and selling its GuideLiner guide extension catheter. As part of the settlement agreement, all litigation between the two parties related to guide extension will be dismissed. The terms of the settlement are confidential.
News For VASC;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
08:03 EDTVASCVascular Solutions receives FDA clearance for Gel-Block 10x embolization product
Subscribe for More Information
November 20, 2014
07:31 EDTBSXBoston Scientific should be bought on weakness, says RBC Capital
Subscribe for More Information
November 19, 2014
12:11 EDTBSXBoston Scientific says Synergy stent met primary endpoint in trial
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. Additionally, favorable rates for key secondary endpoints were observed with the SYNERGY Stent. Dean Kereiakes, M.D., F.A.C.C., F.S.C.A.I., the principal investigator for the EVOLVE II Trial, presented the study results today in a Late Breaking Clinical Trial session at the American Heart Association Scientific Session 2014 in Chicago. Key findings for the SYNERGY Stent from the EVOLVE II Trial include the following: At 12 months, the TLF rate was 6.4% per protocol and 6.7% for intent-to-treat. Stent Thrombosis was rare, with Definite or Probable ST occurring in only 0.4% of patients through one year. No Definite ST occurred after 24 hours.
06:30 EDTBSXJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
11:35 EDTBSXBoston Scientific November volatility elevated into investor day
Subscribe for More Information
07:37 EDTBSXStifel to hold a conference
Subscribe for More Information
06:08 EDTBSXBoston Scientific to host investor meeting
Investor meeting to be held on November 19 at 2 pm. Webcast Link
November 17, 2014
09:08 EDTBSXBoston Scientific announces first U.S. procedures with Symphion completed
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use